CA-4948 - (TakeAim Lymphoma)

July 22, 2026: Curis, Inc. (NASDAQ: CRIS) announced it will host a webcast at 8:30 a.m. ET to discuss updated clinical data from the TakeAim Lymphoma study of emavusertib (CA-4948; IRAK4/FLT3 inhibitor) plus ibrutinib in primary CNS lymphoma (PCNSL) and to provide updated year-end guidance for the TakeAim CLL study of emavusertib plus zanubrutinib in chronic lymphocytic leukemia (CLL).

TakeAim Lymphoma (PCNSL; CA-4948-101; NCT03328078): Updated ORR results (as of July 1, 2026) were 86% (6/7) in BTK inhibitor (BTKi)-naïve patients (100% ORR among evaluable patients, 5/5) and 26% (10/39) in BTKi-experienced patients (33% ORR among evaluable patients, 10/30). Prior data (as of May 1, 2025) are also provided for comparison. Curis noted prior FDA and EMA CHMP interactions indicating the ongoing single-arm PCNSL study could support an accelerated approval application in relapsed/refractory PCNSL.

TakeAim CLL (CA-4948-203; NCT07271667): Curis increased consented patients to 10, expects the first five to be dosed by end of July 2026, and raised December 2026 initial data guidance from 5 patients to 5–10 patients.